Stock A195940 HK INNO.N CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials HK inno.N Corporation

Equities

A195940

KR7195940002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-13 pm EDT 		5-day change 1st Jan Change
35,750 KRW +0.28% Intraday chart for HK inno.N Corporation -4.16% -19.57%
Apr. 04 Protium Science Co.,Ltd. announced that it has received KRW 2 billion in funding from HK inno.N Corporation CI
2022 Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada CI

Valuation

Fiscal Period: December 2021 2022 2023 2024
Capitalization 1 1,517,486 1,012,794 1,012,794 1,012,794
Enterprise Value (EV) 2 1,943 1,050 1,320 1,255
P/E ratio 53.4 x 27.6 x 21.6 x 16.2 x
Yield - 0.9% 0.9% 0.96%
Capitalization / Revenue 1.97 x 1.24 x 1.22 x 1.12 x
EV / Revenue 2.52 x 1.24 x 1.6 x 1.39 x
EV / EBITDA 23.5 x 12 x 13.7 x 9.92 x
EV / FCF 715 x 27.4 x 22.5 x 13.9 x
FCF Yield 0.14% 3.65% 4.44% 7.22%
Price to Book 1.32 x 0.87 x 0.84 x 0.81 x
Nbr of stocks (in thousands) 28,904 28,330 28,330 28,330
Reference price 3 52,500 35,750 35,750 35,750
Announcement Date 2/9/22 3/10/23 - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024
Net sales 1 598.4 769.8 846.5 827.2 900.3
EBITDA 1 - 82.57 87.37 96.09 126.5
EBIT 1 - 50.32 52.53 65.84 91.38
Operating Margin - 6.54% 6.2% 7.96% 10.15%
Earnings before Tax (EBT) 1 - 27.78 37.82 51.79 77
Net income 1 - 24.74 38.13 47.07 63.3
Net margin - 3.21% 4.5% 5.69% 7.03%
EPS 2 1,257 984.0 1,342 1,657 2,205
Free Cash Flow 3 - 2,720 38,262 58,600 90,590
FCF margin - 353.32% 4,519.94% 7,083.93% 10,062.54%
FCF Conversion (EBITDA) - 3,293.92% 43,794.21% 60,986.35% 71,617.48%
FCF Conversion (Net income) - 10,995.49% 100,335.62% 124,508.05% 143,104.59%
Dividend per Share 2 - - 320.0 320.0 342.7
Announcement Date 3/31/21 2/9/22 3/10/23 - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 180.2 251.9 198.2 216.3 201.8 210.6 219.9 221.6
EBITDA - - - - - - - -
EBIT 1 4.23 17.66 22.26 8.38 5.95 13.08 21.74 22.13
Operating Margin 2.35% 7.01% 11.23% 3.87% 2.95% 6.21% 9.89% 9.99%
Earnings before Tax (EBT) 1 - 15 19.12 3.1 5.2 10.27 19.27 19.4
Net income 1 - 13.48 14.96 2.292 2.9 8.125 14.2 14.76
Net margin - 5.35% 7.55% 1.06% 1.44% 3.86% 6.46% 6.66%
EPS - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 5/9/22 8/2/22 10/31/22 3/10/23 - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024
Net Debt 1 - 426 309 307 242
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) - 5.159 x 3.201 x 3.2 x 1.916 x
Free Cash Flow 2 - 2,720 38,262 58,600 90,590
ROE (net income / shareholders' equity) - 2.64% 3.29% 3.96% 5.13%
ROA (Net income/ Total Assets) - 1.43% 2.09% 2.58% 3.26%
Assets 1 - 1,726 1,820 1,825 1,945
Book Value Per Share 3 - 39,819 40,873 42,778 44,028
Cash Flow per Share 3 - - 2,062 2,980 3,551
Capex 1 - 24.1 20.3 27.1 32.9
Capex / Sales - 3.13% 2.4% 3.28% 3.66%
Announcement Date 3/31/21 2/9/22 3/10/23 - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for HK inno.N Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
35,750 KRW
Average target price
53,917 KRW
Spread / Average Target
+50.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
HK INNO.N CORPORATION Stock HK inno.N Corporation
-19.57% 734M
MERCK KGAA Stock Merck KGaA
+19.36% 80.64B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+15.93% 9.07B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+42.06% 4.68B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-22.01% 4.53B
YUHAN CORPORATION Stock Yuhan Corporation
+8.28% 4.06B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-26.61% 2.21B
INDIVIOR PLC Stock Indivior PLC
+11.22% 2.19B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+11.64% 2B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-42.69% 1.82B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A195940 Stock
  4. Financials HK inno.N Corporation